SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Quantifying Components of Drug Expenditure Inflation: The British Columbia Seniors' Drug Benefit Plan
8 references·0 citing·30 second hop
Quantifying Components of Drug Expenditure Inflation: The British Columbia Seniors' Drug Benefit Plan (2002)Quantifying Components of Drug Expenditur…Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs. (2001)Impact of reference-based pri…Adverse Events Associated With Prescription Drug Cost-Sharing Among Poor and Elderly Persons (2001)Adverse Events Associated Wit…Explaining Drug Spending Trends: Does Perception Match Reality? (2000)Explaining Drug Spending Tren…Chapter 3 Medical care prices and output (2000)Chapter 3 Medical care prices…Prescription drug spending: the impact of age and chronic disease status. (1997)Prescription drug spending: t…Essays in Index Number Theory (1993)Essays in Index Number TheoryA Critical Analysis of Studies of State Drug Reimbursement Policies: Research in Need of Discipline (1993)A Critical Analysis of Studie…The economic theory of index numbers: a survey (1981)The economic theory of index …The Demand for Health: A Theoretical and Empirical Investigation (1975)The incidence of mandated maternity benefits. (1994)Productivity Measurement Issues in Services Industries: "Baumol's Disease" Has Been Cured (2003)Productivity in the services sector: conventional and current explanations (2011)Where Are the Health Care Entrepreneurs? The Failure of Organizational Innovation in Health Care (2011)1. On the Concept of Health Capital and the Demand for Health (2017)Employee Benefit Research Institute (1988)Who's the Fairest of Them All? Which Provincial Pharmacare Model Would Best Protect Canadians Against Catastrophic Drug Costs? (2004)Cost Sharing and the Initiation of Drug Therapy for the Chronically Ill (2009)Price regulation of drugs: Lessons from Germany (1996)The Strategic Response by Pharmaceutical Firms to the Medicaid Most-Favored-Customer Rules (1996)Pharmaceutical Reference Prices (1998)Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers (2003)A therapeutic substitution policy for proton pump inhibitors: Clinical and economic consequences (2006)Free for All? Lessons from the RAND Health Insurance Experiment (1995)Pharmacy Benefits and the Use of Drugs by the Chronically Ill (2004)Prescription drug cost sharing: associations with medication and medical utilization and spending and health. (2007)Medical Bankruptcy in the United States, 2007: Results of a National Study (2009)Facets of Balassa‐Samuelson Thirty Years Later* (1994)Product quality and the direction of trade (2005)Estimating Cross-Country Differences in Product Quality* (2011)The Case for a Medicare Drug Coverage Benefit: A Critical Review of the Empirical Evidence (2001)The U.S. Pharmaceutical Industry: Why Major Growth In Times Of Cost Containment? (2001)Pharmaceutical Risk-Sharing Agreements (2008)Consumer Prices, the Consumer Price Index, and the Cost of Living (1998)The Next Generation of the Penn World Table (2015)Productivity Growth, Technical Progress, and Efficiency Change in Industrialized Countries (2016)Inadequate Prescription-Drug Coverage for Medicare Enrollees — A Call to Action (1999)Transforming Insurance Coverage Into Quality Health Care (2000)Effective healthcare cost-containment policies: A systematic review (2018)
this work references cited by second hop

References

  • 2001Adverse Events Associated With Prescription Drug Cost-Sharing Among Poor and Elderly Persons873 cited
  • 1981The economic theory of index numbers: a survey314 cited
  • 1993A Critical Analysis of Studies of State Drug Reimbursement Policies: Research in Need of Discipline169 cited
  • 1993Essays in Index Number Theory140 cited
  • 2000Explaining Drug Spending Trends: Does Perception Match Reality?120 cited
  • 1997Prescription drug spending: the impact of age and chronic disease status.96 cited
  • 2000Chapter 3 Medical care prices and output88 cited
  • 2001Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs.60 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work